Adjuvants Immunologic/*therapeutic use Administration Intravesical BCG Vaccine/*therapeutic use Carcinoma Transitional Cell/pathology/*therapy Cystoscopy Female Humans Male Multivariate Analysis Muscle Smooth/*pathology Neoplasm Invasiveness Neoplasm Recurrence Local/*epidemiology Proportional Hazards Models Sex Factors Survival Rate Urinary Bladder Neoplasms/pathology/*therapy *Urologic Surgical Procedures Bladder cancer Gender differences Local recurrence Meta-analysis Transurethral resection of bladder tumor

Administration Intravesical Aged Aged 80 and over BCG Vaccine/*therapeutic use Biopsy Needle Disease-Free Survival Female Humans Immunohistochemistry Immunotherapy/*methods In Situ Hybridization Fluorescence Male Middle Aged Neoplasm Recurrence Local/mortality/*pathology Predictive Value of Tests Prognosis Risk Assessment Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/mortality/pathology/*therapy Bcg Bladder cancer Immunotherapy Personalized therapy Response prediction

Antibiotics Antineoplastic/*therapeutic use BCG Vaccine/*therapeutic use Combined Modality Therapy Humans Mitomycin/*therapeutic use Urinary Bladder Neoplasms/*drug therapy bacillus Calmette-Guérin mitomycin C non-muscle-invasive bladder carcinoma recurrence rate meta-analysis.

Adjuvants Immunologic/*therapeutic use BCG Vaccine/*therapeutic use Humans Mycobacterium bovis Urinary Bladder Neoplasms/*drug therapy/pathology BCG vaccine immunotherapy urinary bladder neoplasms